When was Cantargia founded?

Cantargia was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Where is Cantargia located?

Cantargia is headquartered in Lund, Sweden.

How many employees does Cantargia have?

As of May 31, 2026, the latest employee count at Cantargia is 32.

Is Cantargia a funded company?

Cantargia is a funded company, having raised a total of $1M across 3 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Jul 05, 2013.

When was the latest funding round of Cantargia?

Cantargia's latest funding was a $***** Post IPO round on Dec 15, 2020, with participation from 0 investor.

Where does Cantargia rank among its competitors?

Cantargia ranks 386th amongst 3284 active competitors, of which 1134 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Cantargia?

Cantargia's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Cantargia - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of antibody-based therapy for the treatment of solid tumors and cancers. The company's lead product candidate CAN04, to block cancer cell signaling via the interleukin-1 system, which among other things can limit the inflammatory tumor uses for growth and defense strategy. CAN04 also stimulates the body's immune system to eliminate cancer cells.

Key Metrics

Founded Year

2010

Location

Lund, Sweden

Stage

Public

Total Funding

$1M in 3 rounds

Latest Funding Round

Post IPO, Dec 15, 2020, $*****

Investors

HBM Healthcare Investments & 10 more

Ranked

386^th among 3284 active competitors

Employee Count

32 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3042 more

Exit Details

Public

View Cantargia's full profile

Cantargia got listed on Mar 17, 2015.

Click here to take a look at Cantargia's IPO in detail

Cantargia has raised a total funding of $1M over 3 rounds. Its first funding round was on Jul 05, 2013. Cantargia has 11 institutional investors.

Here is the list of recent funding rounds of Cantargia:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 15, 2020	1423997	Post IPO	5787607	2247162	8211270	8074734
Feb 19, 2020	7959455	Post IPO	4167818	6997129	5354584	Swedbank Robur & 7 more
Jul 05, 2013	6068369	PE	2493439	8801896	6661177	Sunstone & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Cantargia's funding rounds and investors

Cantargia's employee count trend

Cantargia has 32 employees as of May 26. Here is Cantargia's employee count trend over the years:

Uncover Cantargia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cantargia include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Cantargia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
386th	Cantargia 2010, Lund (Sweden), Public	Developer of antibody-based therapy for the treatment of solid tumors and cancers	$1M	HBM Healthcare Investments, Handelsbanken ... & 9 others	55/100